Additional Metadata
Persistent URL dx.doi.org/10.1093/annonc/mdw375.01, hdl.handle.net/1765/126455
Journal Annals of Oncology
Citation
Weisel, K, Palumbo, A, Chanan-Khan, A, Nooka, A.K, Spicka, I, Masszi, T, … Sonneveld, P. (2016). Phase 3 randomised study of daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR. Annals of Oncology, 27. doi:10.1093/annonc/mdw375.01